Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth K W To

Showing results (61-70 of 100) with videos related to

Pageof 10
Sort By:
Current Cancer Drug Targets|November 2, 2018
The RNA Binding Protein HuR: A Promising Drug Target for Anticancer TherapyMingxia Wu, Christy W S Tong, Wei Yan, et al.
Pharmaceutics|July 30, 2025
Recent Advances in the Use of <i>Ganoderma lucidum</i> and <i>Coriolus versicolor</i> Mushrooms to Enhance the Anticancer Efficacy of EGFR-Targeted Drugs in Lung CancerHang Zhang, Longling Wang, Yuet Wa Chan, et al.
Seminars in Cancer Biology|May 13, 2025
HDAC inhibitors: Cardiotoxicity and paradoxical cardioprotective effect in ischemia-reperfusion myocardiocyte injuryKenneth K W To, Seda S Tolu, Longling Wang, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 16, 2004
Leu-574 of human HIF-1alpha is a molecular determinant of prolyl hydroxylationYukio Kageyama, Minori Koshiji, Kenneth K W To, et al.
Bioorganic & Medicinal Chemistry|September 11, 2004
Protein phosphatase 2A inhibition and circumvention of cisplatin cross-resistance by novel TCM-platinum anticancer agents containing demethylcantharidinKenneth K W To, Xinning Wang, Chun Wing Yu, et al.
International Journal of Pharmaceutics|January 10, 2012
Reversal of P-glycoprotein-mediated multidrug resistance by a synthetic α-aminoxy peptidomimeticBin Ma, Stella Chai, Na Li, et al.
Molecular Cell|March 23, 2005
HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expressionMinori Koshiji, Kenneth K-W To, Stefanie Hammer, et al.
Expert Opinion on Drug Discovery|November 20, 2019
Advances in the discovery of microRNA-based anticancer therapeutics: latest tools and developmentsKenneth K W To, Winnie Fong, Christy W S Tong, et al.
Signal Transduction and Targeted Therapy|August 29, 2020
Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancerMin Luo, Fang Wang, Hong Zhang, et al.
European Journal of Medicinal Chemistry|July 22, 2015
Reversal of P-gp and BCRP-mediated MDR by tariquidar derivativesXu-Qin Li, Lin Wang, Yan Lei, et al.
Pageof 10

Showing results (61-70 of 100) with videos related to

Sort By:
Pageof 10
Current Cancer Drug Targets|November 2, 2018
The RNA Binding Protein HuR: A Promising Drug Target for Anticancer TherapyMingxia Wu, Christy W S Tong, Wei Yan, et al.
Pharmaceutics|July 30, 2025
Recent Advances in the Use of <i>Ganoderma lucidum</i> and <i>Coriolus versicolor</i> Mushrooms to Enhance the Anticancer Efficacy of EGFR-Targeted Drugs in Lung CancerHang Zhang, Longling Wang, Yuet Wa Chan, et al.
Seminars in Cancer Biology|May 13, 2025
HDAC inhibitors: Cardiotoxicity and paradoxical cardioprotective effect in ischemia-reperfusion myocardiocyte injuryKenneth K W To, Seda S Tolu, Longling Wang, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 16, 2004
Leu-574 of human HIF-1alpha is a molecular determinant of prolyl hydroxylationYukio Kageyama, Minori Koshiji, Kenneth K W To, et al.
Bioorganic & Medicinal Chemistry|September 11, 2004
Protein phosphatase 2A inhibition and circumvention of cisplatin cross-resistance by novel TCM-platinum anticancer agents containing demethylcantharidinKenneth K W To, Xinning Wang, Chun Wing Yu, et al.
International Journal of Pharmaceutics|January 10, 2012
Reversal of P-glycoprotein-mediated multidrug resistance by a synthetic α-aminoxy peptidomimeticBin Ma, Stella Chai, Na Li, et al.
Molecular Cell|March 23, 2005
HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expressionMinori Koshiji, Kenneth K-W To, Stefanie Hammer, et al.
Expert Opinion on Drug Discovery|November 20, 2019
Advances in the discovery of microRNA-based anticancer therapeutics: latest tools and developmentsKenneth K W To, Winnie Fong, Christy W S Tong, et al.
Signal Transduction and Targeted Therapy|August 29, 2020
Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancerMin Luo, Fang Wang, Hong Zhang, et al.
European Journal of Medicinal Chemistry|July 22, 2015
Reversal of P-gp and BCRP-mediated MDR by tariquidar derivativesXu-Qin Li, Lin Wang, Yan Lei, et al.
Pageof 10